Statements


Statement

  • 19 May 2021

Statement on dolutegravir use in pregnancy & for women of childbearing potential


Statement

  • 16 Jun 2020

Professor Ebrahim Variava


Position statement of SAHCS on service delivery to TB patients (drug-susceptible and drug-resistant) during the COVID-19 pandemic

Contributors: T Boyles, F Conradie, V Cox, A Grimsrud, J Hughes, J Nel, A Reuter, L Wilkinson

  • 28 Mar 2020

To support TB patients during the COVID-19 pandemic, it is critical both to patients and the healthcare system to minimise visits to health facilities. This document outlines key adaptations to the TB care service delivery that should be considered to reduce health facility visits during the COVID-19 pandemic. This guidance prioritises how to provide uninterrupted TB treatment in resource constrained health systems with a high burden of TB. In addition to outlining recommended service delivery approaches for drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) patients, guidance on additional areas (including patient support, contact tracing, provision of the influenza vaccine, differentiating TB from COVID-19 and telephonic monitoring) is provided.


Statement

  • 23 Mar 2020

Provision of 6 months on antiretroviral treatment - Position statement from the Southern African HIV Clinician Society


COVID-19

  • 11 Mar 2020

Recommendations from the Southern African HIV Clinicians Society (SAHCS) for COVID-19


Statement

  • 12 Jun 2019

The Southern African HIV Clinicians Society states its support for the decriminalisation of drug use





Statement

  • 10 May 2018

North-West Province: A health system on its knees


Statement

  • 29 Mar 2018

The Southern African Journal of HIV Medicine accepted onto PubMed Central®


Statement

  • 15 Mar 2018

Statement on 5-FC for cryptococcal meningitis.


Statement

  • 15 Sep 2017

Southern African HIV Clinicians Society supports DA call for greater provincial health funding


Statement

  • 26 May 2017

Society statement on the release of the SALRC report


Statement

  • 17 Mar 2017

Doctor who promoted unproven sex gel loses court case against the SA HIV Clinicians Society





Statement on the Increase of CD4 Threshold to 500 for Initiation of ART

  • 24 Jul 2014

Following the announcement by the Minister of Health, Hon Dr Aaron Motsoaledi, that South Africa will increase the CD4 threshold for antiretroviral therapy to 500 in January 2015. Prof Graeme Meintjes, on behalf of the Society's Adult ART guideline committee, outlines the Society’s position on ART initiation in patients with a CD4 count between 350-500


Statement on the Mississippi baby

  • 14 Jul 2014

The Society notes the positive impacts arising from the case of the Mississippi baby, despite the disappointment felt at the news that the child now has a detectable viral load. 


Fixed dose combination advice

  • 22 May 2014

A guide for clinicians and programme managers on how to switch from 3 separate antiretroviral (ARV) drugs to the new, single, fixed-dose combination (FDC) tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV).






Letter to Public Sector Clinicians Regarding FDC

  • 23 Apr 2013

This is a letter from the South African HIV Clinicians Society to public sector clinicians regarding private sector patients transferring in on the FDC tablets, including the approach and management to be taken to introducing FDC treatment.


Letter to Private Sector Clinicians Regarding FDC

  • 23 Apr 2013

This letter is from the Southern African HIV Clinicians Society to clinicians in the private sector regarding the prescribing of FDC tablets to public sector patients including the approach and management for phasing in the FDC treatment.


CDC Statement in Response to VOICE Trial Results

  • 06 Mar 2013

In wake of latest trial results, the CDC stresses that consistent use is imperative when using Pre-Exposure Prophylaxis to prevent HIV infection. This statement can be attributed to Jonathan Mermin, M.D., Director of CDC’s Division of HIV/AIDS Prevention


Results of VOICE Study by MTN

  • 06 Mar 2013

The Microbicide Trials Network released the following results of a major HIV prevention trial, known as the VOICE trial. The results suggest that daily use of a product – whether a vaginal gel or an oral tablet – does not appear to be the right approach for preventing HIV in young, unmarried African women.